# Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers

> **NCT00490945** · PHASE2 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 45 (actual)

## Conditions studied

- Circadian Rhythm Sleep Disorders

## Interventions

- **DRUG:** VEC-162

## Key facts

- **NCT ID:** NCT00490945
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-07
- **Primary completion:** 2005-03
- **Final completion:** 2005-03
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2014-08-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00490945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00490945, "Safety and Efficacy of VEC-162 on Circadian Rhythm in Healthy Adult Volunteers". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00490945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*